Advertisement


Philip Bonomi, MD, on SBRT and Surgery for Localized Disease

2015 IASLC World Conference on Lung Cancer

Advertisement

Philip Bonomi, MD, of Rush Medical College, summarizes a debate on two important issues: choosing between surgery and stereotactic body radiation therapy (SBRT) in operable NSCLC, and whether or not to use SBRT for nonbiopsied lung nodules (Abstract PC 01).



Related Videos

Lung Cancer

Tony Mok, MD, and Fred R. Hirsch, MD, PhD: Summary of the IASLC Presidential Symposium

Tony Mok, MD, of The Chinese University of Hong Kong, and Fred R. Hirsch, MD, PhD, of University of Colorado Health Science Center discuss the highlights of the featured plenary session, which included the conference’s top four abstracts (Abstract PLEN04).

Lung Cancer

Christine D. Berg, MD, on Screening for Lung Cancer in Those at High Risk

Christine D. Berg, MD, of Johns Hopkins Medicine, discusses how increased insurance coverage should dramatically increase lung cancer screening. If done correctly—which will be a challenge—screening will help improve the prognosis of patients with lung cancer (Abstract PLEN 01.01).

Lung Cancer

Fred R. Hirsch, MD, PhD, and Paul A. Bunn, Jr., MD, on the Highlights of the World Conference on Lung Cancer

Fred R. Hirsch, MD, PhD, of the University of Colorado Health Science Center, and Paul A. Bunn, Jr, MD, of the University of Colorado Cancer Center, give their views on the goals and important presentations of the 2015 World Conference on Lung Cancer.

Lung Cancer
Symptom Management

Philip Bonomi, MD, on Results of the Romana 1 and Romana 2 Trials

Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).

Lung Cancer

Roy S. Herbst, MD, PhD, on Results From SWOG S0819

Roy S. Herbst, MD, PhD, of the Smilow Cancer Hospital at Yale Cancer Center, discusses his findings of a phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in advanced non–small cell lung cancer (Abstract PLEN04.01).

Advertisement

Advertisement



Advertisement